X4 Pharmaceuticals’ Mavorixafor could become a safer treatment for CN and the 4WARD Phase 3 trial in CN will be key. Click for my latest analysis of XFOR stock.
The infection rate of one type of carbapenem-resistant Enterobacterales bacteria has risen by more than 460 percent in recent years. Scientists say people receiving treatment in hospitals are at ...
Proteomic analysis of cerebrospinal fluid (CSF) has the potential to provide insight into the pathophysiology of aneurysmal subarachnoid hemorrhage (aSAH) and target trials to improve outcome. The aim ...
Scientists at the Institute for Basic Science (IBS) have uncovered a non-invasive method to boost the brain’s natural waste drainage system—a discovery that they suggest could open new avenues for ...
Copyright: © 2025 The Author(s). Published by Elsevier Ltd. CRP in CSF was measured in 103 adult patients from Denmark, which included 34 (33%) bacterial meningitis ...
Washington, D.C, December 3, 2024. The Commercial Space Federation (CSF) has announced a rebrand of the organization (previously Commercial Spaceflight Federation) to better recognize the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback